drugset / Press release
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
2024-12-02 · ADARx Pharmaceuticals, Inc. · original adarx.com ↗
Recruiting Status: Recruiting Age: 18 – 65 Years Old This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases. Learn More
The release as fetched from its publisher. adarx.com ↗